Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neulasta® Clear all

Conditions: Leukemia
Interventions: Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions: Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 72
States / cities: Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more

Conditions: Breast Cancer
Interventions: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim; Drug
Lead sponsor: University of Tennessee Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Memphis, Tennessee • Fort Worth, Texas

Conditions: Healthy Volunteers
Interventions: PEGFILGRASTIM; Drug
Lead sponsor: Adello Biologics, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions: Mitomycin-C, Pegfilgrastim; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions: Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim; Drug · Other · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test; Drug · Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 12 Years to 45 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Chemotherapy-induced Neutropenia, Breast Cancer
Interventions: LA-EP2006, Neulasta®; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 10
States / cities: Hot Springs, Arkansas • Jonesboro, Arkansas • Corona, California + 7 more

Conditions: Ovarian Cancer
Interventions: Docetaxel, Carboplatin, Pegylated G-CSF; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globin (ATG), Placebo, Pegylated GCSF; Drug
Lead sponsor: University of Florida; Other
Eligibility: 12 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Cabazitaxel, Mitoxantrone, Prednisone, Pegfilgrastim; Drug
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • San Francisco, California • Nashville, Tennessee

Conditions: Neutropenia, Breast Cancer
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 49
States / cities: Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions: XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Lymphocytic Leukemia
Interventions: Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab, Filgrastim; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Sedona, Arizona • Denver, Colorado + 23 more

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Medulloblastoma
Interventions: Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention; Procedure · Drug · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 59 Months
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 10
States / cities: Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more

Conditions: High Grade Glioma, CNS Tumor
Interventions: Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery; Drug · Biological · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 3 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Breast Cancer
Interventions: Pre operativeTrastuzumab, ABI-007 (Abraxane), Vinorelbine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Neutropenia
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Glendale, Arizona • Scottsdale, Arizona • Fresno, California + 7 more

Conditions: Healthy
Interventions: CHS-1701, Pegfilgrastim; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 4
States / cities: Cypress, California • Cincinnati, Ohio • San Antonio, Texas + 1 more

Search by objective public record fields.

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Neulasta in Type 1 Diabetes

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Reversing Type 1 Diabetes After it is Established

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta